Strangvac, a vaccine against equine strangles, is now available for sale in Poland

Stockholm, November 28, 2022 – Intervacc AB (publ) announces today that Strangvac® is now available for sale in Poland. Dechra Pharmaceuticals PLC distributes the vaccine in Poland and in a number of other European countries.

Poland with its approximately 300 000 horses, has a long tradition within equestrian sport and outbreaks of the highly contagious infectious disease strangles affects horses and horse owners around the country.

“I have investigated outbreaks of strangles in horses for many years, helping to track the causal agent, Streptococcus equi, as it spreads through horse populations around the world, including Poland. The launch of Strangvac® in Poland provides us with a new tool to reduce the health and economic impact of this terrible disease, keeping our horses safe.”, says Dr Lucjan Witkowski from the Institute of Veterinary Medicine at University of Warsaw.

“Strangvac® is approved for sale and marketing in the EU as well as the UK and Norway. Strangvac® has been launched in Sweden, Denmark, the UK, France, Germany, the Benelux region, Austria, Ireland and now also in Poland. Outbreaks of equine strangles occur regularly and the disease cause great suffering and economic cost in the region and across Europe. Poland is an important equine market, and this is significant milestone for our continued launch around Europe.” comments Andreas Andersson, CEO of Intervacc.

For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on November 28, 2022, 11.45 CET.

About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10